Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to follow the study schedule, including visits, treatments, and tests as required by the trial
- People aged between 3 and 25 years (inclusive) at the time of signing the consent form, either male or female
- People who have been diagnosed with B-cell acute lymphoblastic leukaemia (a type of blood cancer) that has come back or stopped responding to treatment
- People whose bone marrow test at screening shows more than 5% abnormal cancer cells (blasts)
- People whose cancer cells carry a specific marker called CD19, confirmed by a laboratory test on bone marrow or blood at screening
- People with a specific type of this leukaemia linked to the Philadelphia chromosome (Ph+), provided they meet the relapsed/refractory criteria and have either tried and failed at least two targeted drug treatments (called TKIs), cannot tolerate TKIs, or have a medical reason they cannot use TKIs — unless a specific genetic mutation called T315I is present (confirm with trial site)
- People whose doctors estimate they are likely to survive for more than 3 months
Who may not be able to join:
- People whose leukaemia has returned only in areas outside the bone marrow (isolated extramedullary relapse)
- People diagnosed with Burkitt lymphoma or Burkitt leukaemia (a related but different type of blood cancer)
- People who have had active or moderate-to-severe graft-versus-host disease (a complication that can occur after a stem cell transplant) within the 4 weeks before signing the consent form, or who have received any treatment for this condition within 4 weeks before the treatment infusion
- People who have an active infection that is not under control at the time of signing the consent form or at the time of the cell collection procedure
- People who have previously received any CAR-T cell therapy or other cell or gene-based therapy
- People who have received experimental drugs or cancer-fighting treatments within 4 weeks, or within 5 times the drug's natural clearing time from the body (whichever period is longer), before the cell collection procedure
- People who have active lung inflammation or lung disease at the time of signing the consent form
- People whom the trial doctors consider unable to follow the study requirements, or who are otherwise not suitable for the trial for any reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaojun Huang, Peking University People's Hospital
Phone: 010-88325229
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Objective response rate after S1904 infusion [Effectiveness]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.